Shanghai Junshi Biosciences (HKG:1877, SHA:688180) obtained approval from Australia's Therapeutic Goods Administration (TGA) to market the drug toripalimab, according to a Hong Kong Stock Exchange disclosure on Jan. 17.
The TGA approved the new chemical entity application for toripalimab in combination with cisplatin and gemcitabine as a treatment for adults with metastatic or recurrent, locally advanced nasopharyngeal carcinoma or NPC.
Toripalimab was also approved as a single agent to treat adults with unresectable or metastatic NPC with disease progression on or after platinum-containing chemotherapy, the filing said.
The pharmaceutical company's Shanghai shares rose more than 1% and Hong Kong shares climbed less than 2% in recent trade.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。